文献速递心脑血管急症

亚洲心房颤动与卒中的全球负担:心房颤动临床流行病学系统综述

The Global Burden of Atrial Fibrillation and Stroke: A Systematic Review of the Clinical Epidemiology of Atrial Fibrillation in Asia.
PubMed 文献 · Chest · 2017-04-17
一句话结论亚洲房颤发病率与患病率近年上升,社区研究中华法林使用率中国1.0%-4.1%、日本49.1%-70.0%,医院研究普遍<50%。

本更新系统综述纳入来自亚洲8个国家的58篇文献,旨在呈现亚洲房颤流行病学现状、通过Meta分析探索房颤发病率与卒中风险,并研究房颤相关缺血性卒中的真实世界抗血栓药物使用。汇总年发病率为5.38/1000人年(95%CI 4.53-6.24,I²=99.5%,n=10),房颤患者缺血性卒中年风险为3.0%(1.60%-4.95%,I²=99.8%,n=8)。医院与社区来源的房颤患病率分别为0.37%-3.56%和2.8%-15.8%。社区研究中中国受试者华法林使用率为1.0%-4.1%,日本为49.1%-70.0%;医院研究中华法林使用率<50%。

要点

  • 亚洲房颤汇总年发病率为5.38/1000人年(95%CI 4.53-6.24,I²=99.5%,n=10)。
  • 房颤患者缺血性卒中汇总年风险为3.0%(95%CI 1.60%-4.95%,I²=99.8%,n=8)。
  • 社区来源房颤患病率2.8%-15.8%,医院来源0.37%-3.56%。
  • 社区研究中华法林使用率中国受试者1.0%-4.1%、日本受试者49.1%-70.0%,医院研究<50%。
  • 房颤发病率与患病率近年上升,但亚洲各国内部变异仍大。

适用人群与场景

  • 亚洲8个国家的房颤人群,涵盖医院来源与社区来源研究。

研究设计与关键结果

  • 系统综述纳入来自亚洲8个国家的58篇文献,为更新版系统综述。
  • 房颤汇总年发病率为5.38/1000人年(95%CI 4.53-6.24,I²=99.5%,n=10)。
  • 对医院和社区研究行Meta分析,房颤患者缺血性卒中汇总年风险为3.0%(95%CI 1.60%-4.95%,I²=99.8%,n=8)。
  • 医院来源房颤患病率0.37%-3.56%,社区来源2.8%-15.8%。
  • 社区研究中缺血性卒中在房颤患者中的患病率1.9%-6.0%,医院研究中0.36%-28.3%。
  • 社区研究中华法林使用率中国受试者1.0%-4.1%,日本受试者49.1%-70.0%。
  • 医院研究中华法林使用率<50%。

证据类型、等级与局限

  • 证据类型:系统综述与Meta分析,异质性用I²检验。
  • 局限:房颤年发病率汇总异质性I²=99.5%,房颤患者缺血性卒中年风险汇总异质性I²=99.8%。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「对床旁实践的改变」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Our previous review reported great variability in the incidence and prevalence of atrial fibrillation (AF) in non-Western cohorts, especially from Asian countries; in recent years, epidemiologic studies on AF have been increasingly reported from Asia.

METHODS: The goal of this updated systematic review was to present the current knowledge base of AF epidemiology in Asian countries since our previous review. We also explored AF incidence and the risk of stroke in AF by using a meta-analysis, with I2 testing the heterogeneity. Third, "real-world" antithrombotic drug use for ischemic stroke (IS) prevention associated with AF was studied.

RESULTS: A total of 58 articles from eight countries in Asia were included in the analysis. The summary annual incidence of AF was 5.38 (95% CI, 4.53-6.24; I2 = 99.5%; n = 10) per 1,000 person-years, and the IS annual risk in AF was 3.0% (1.60%-4.95%; I2 = 99.8%; n = 8) when meta-analysis was performed on hospital- and community-based studies. Hospital- and community-based AF prevalence ranged from 0.37% to 3.56% and 2.8% to 15.8%, respectively. IS prevalence in AF ranged from 1.9% to 6.0% and 0.36% to 28.3% in community- and hospital-based studies. Warfarin use in Chinese subjects is relatively low (1.0%-4.1%) compared with Japanese subjects (49.1%-70.0%) in community-based studies. The rate of warfarin use was < 50% in hospital-based studies.

CONCLUSIONS: The incidence and prevalence of AF have increased in recent years, although great variability still exists in Asian countries. Variability in annual IS risk in patients with AF was apparent between hospital- and community-based studies. However, the rate of warfarin use was < 50% in hospital studies from Asian countries.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Bai Y, Wang YL, Shantsila A, et al. The Global Burden of Atrial Fibrillation and Stroke: A Systematic Review of the Clinical Epidemiology of Atrial Fibrillation in Asia. Chest. 2017. PMID: 28427968. doi:10.1016/j.chest.2017.03.048

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。